Cargando…
Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury
BACKGROUND: Keratin 8 and 18 (K8/K18) cytoskeletal proteins protect hepatocytes from undergoing apoptosis and their mutations predispose to adverse outcomes in acute liver failure (ALF). All known K8/K18 variants occur at relatively non-conserved residues and do not cause keratin cytoskeleton reorga...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545365/ https://www.ncbi.nlm.nih.gov/pubmed/26286715 http://dx.doi.org/10.1186/s12916-015-0418-0 |
_version_ | 1782386746065944576 |
---|---|
author | Usachov, Valentyn Urban, Thomas J. Fontana, Robert J. Gross, Annika Iyer, Sapna Omary, M. Bishr Strnad, Pavel |
author_facet | Usachov, Valentyn Urban, Thomas J. Fontana, Robert J. Gross, Annika Iyer, Sapna Omary, M. Bishr Strnad, Pavel |
author_sort | Usachov, Valentyn |
collection | PubMed |
description | BACKGROUND: Keratin 8 and 18 (K8/K18) cytoskeletal proteins protect hepatocytes from undergoing apoptosis and their mutations predispose to adverse outcomes in acute liver failure (ALF). All known K8/K18 variants occur at relatively non-conserved residues and do not cause keratin cytoskeleton reorganization, whereas epidermal keratin-conserved residue mutations disrupt the keratin cytoskeleton and cause severe skin disease. The aim of our study was to identify keratin variants in idiosyncratic drug-induced liver injury (DILI). METHODS: Genomic DNA was isolated from 800 patients enrolled in an ongoing US multicenter study, with DILI attributed to a wide range of drugs. Specific K8/K18 exonic regions were PCR-amplified and screened by denaturing HPLC followed by DNA sequencing. The functional impact of keratin variants was assessed using cell transfection and immune staining. RESULTS: Heterozygous and compound amino acid-altering K8/K18 variants were identified in 86 DILI patients and non-coding variants in 15 subjects. Five novel amino acid-altering (K8 Lys393Arg, K8 Ala351Val, K8 Ala358Val, K8 Ile346Val, K18 Asp89His) and two non-coding variants were observed. Several variants segregated with specific ethnic backgrounds but were found at similar frequencies in DILI subjects and ethnically matched population controls. Notably, variants in highly conserved residues of K8 Lys393Arg (ezetimibe/simvastatin-related) and K18 Asp89His (isoniazid-related) were found in patients with fatal DILI. These novel variants also led to keratin network disruption in transfected cells. CONCLUSIONS: Novel K8/K18 cytoskeleton-disrupting variants were identified in two patients and segregated with fatal DILI. Other non-cytoskeleton-disrupting keratin variants did not preferentially associate with DILI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-015-0418-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4545365 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45453652015-08-23 Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury Usachov, Valentyn Urban, Thomas J. Fontana, Robert J. Gross, Annika Iyer, Sapna Omary, M. Bishr Strnad, Pavel BMC Med Research Article BACKGROUND: Keratin 8 and 18 (K8/K18) cytoskeletal proteins protect hepatocytes from undergoing apoptosis and their mutations predispose to adverse outcomes in acute liver failure (ALF). All known K8/K18 variants occur at relatively non-conserved residues and do not cause keratin cytoskeleton reorganization, whereas epidermal keratin-conserved residue mutations disrupt the keratin cytoskeleton and cause severe skin disease. The aim of our study was to identify keratin variants in idiosyncratic drug-induced liver injury (DILI). METHODS: Genomic DNA was isolated from 800 patients enrolled in an ongoing US multicenter study, with DILI attributed to a wide range of drugs. Specific K8/K18 exonic regions were PCR-amplified and screened by denaturing HPLC followed by DNA sequencing. The functional impact of keratin variants was assessed using cell transfection and immune staining. RESULTS: Heterozygous and compound amino acid-altering K8/K18 variants were identified in 86 DILI patients and non-coding variants in 15 subjects. Five novel amino acid-altering (K8 Lys393Arg, K8 Ala351Val, K8 Ala358Val, K8 Ile346Val, K18 Asp89His) and two non-coding variants were observed. Several variants segregated with specific ethnic backgrounds but were found at similar frequencies in DILI subjects and ethnically matched population controls. Notably, variants in highly conserved residues of K8 Lys393Arg (ezetimibe/simvastatin-related) and K18 Asp89His (isoniazid-related) were found in patients with fatal DILI. These novel variants also led to keratin network disruption in transfected cells. CONCLUSIONS: Novel K8/K18 cytoskeleton-disrupting variants were identified in two patients and segregated with fatal DILI. Other non-cytoskeleton-disrupting keratin variants did not preferentially associate with DILI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-015-0418-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-08-19 /pmc/articles/PMC4545365/ /pubmed/26286715 http://dx.doi.org/10.1186/s12916-015-0418-0 Text en © Usachov et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Usachov, Valentyn Urban, Thomas J. Fontana, Robert J. Gross, Annika Iyer, Sapna Omary, M. Bishr Strnad, Pavel Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury |
title | Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury |
title_full | Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury |
title_fullStr | Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury |
title_full_unstemmed | Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury |
title_short | Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury |
title_sort | prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545365/ https://www.ncbi.nlm.nih.gov/pubmed/26286715 http://dx.doi.org/10.1186/s12916-015-0418-0 |
work_keys_str_mv | AT usachovvalentyn prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury AT urbanthomasj prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury AT fontanarobertj prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury AT grossannika prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury AT iyersapna prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury AT omarymbishr prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury AT strnadpavel prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury AT prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury |